On January 20, 2022 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, reported that company management will present and participate in one-on-one meetings at the B. Riley Securities 2022 Oncology Conference, taking place virtually January 27 – 28, 2022 (Press release, Cardiff Oncology, JAN 20, 2022, View Source [SID1234605625]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the presentation can be found below.
B. Riley Securities 2022 Oncology Conference
Presentation Date:
January 28, 2022
Presentation Time:
2:00 PM ET
Webcast Link:
A replay of the presentation will be available by visiting the "Events" section of the Cardiff Oncology website after its conclusion.